文献速递MDS 与骨髓增殖性肿瘤

MARS:晚期系统性肥大细胞增多症的突变校正风险评分

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.
PubMed 文献 · J Clin Oncol · 2019-09-11

该研究基于383例晚期系统性肥大细胞增多症患者,开发并验证了一个整合临床与突变特征的五参数风险评分MARS。多变量分析识别出年龄>60岁、贫血、血小板减少及高危基因突变等预后因素,据此划分低、中、高三个风险组,中位总生存分别为未达到、3.9年和1.9年,且该评分独立于WHO分类并能预测无白血病生存。

要点

  • MARS评分包含年龄>60岁、血红蛋白<10 g/dL、血小板<100×10^9/L及高危基因突变。
  • 三个风险组中位OS:低危未达到,中危3.9年,高危1.9年(P<.001)。
  • MARS独立于WHO分类,并可预测白血病转化风险。

核心结论

  • MARS是一个经过验证的五参数、独立于WHO分类的预后评分,可定义晚期系统性肥大细胞增多症的三个风险组。

研究设计与样本

  • 多中心回顾性研究,训练集231例来自德国嗜酸性粒细胞与肥大细胞疾病登记,验证集152例来自欧美多个中心。
  • 采用Cox多变量模型筛选总生存的预测变量。

主要发现

  • 多变量分析显示年龄>60岁、贫血(血红蛋白<10 g/dL)、血小板减少(血小板<100×10^9/L)、存在一个高危基因突变(SRSF2、ASXL1和/或RUNX1)及两个或以上高危基因突变与OS相关。
  • 低危组中位OS未达到,中危组3.9年(95%CI 2.1-5.7),高危组1.9年(95%CI 1.3-2.6),P<.001。
  • 中位随访2.2年(范围0-23年)期间,63例(16%)发生白血病转化,其中32%转化为继发性肥大细胞白血病,68%转化为继发性急性髓系白血病。
  • MARS对无白血病生存也有预测作用(P<.001)。

关键数值与推荐

  • 风险因素包括:年龄>60岁、血红蛋白<10 g/dL、血小板<100×10^9/L、一个高危基因突变(SRSF2/ASXL1/RUNX1)、两个或以上高危基因突变。
  • 根据风险比加权积分将患者分为低危、中危和高危三组。

临床怎么用

  • MARS可用于晚期系统性肥大细胞增多症患者的前期治疗分层,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop a risk score for patients with advanced systemic mastocytosis (AdvSM) that integrates clinical and mutation characteristics. PATIENTS AND METHODS: The study included 383 patients with AdvSM from the German Registry on Disorders of Eosinophils and Mast Cells (training set; n = 231) and several centers for mastocytosis in the United States and Europe, all within the European Competence Network on Mastocytosis (validation set; n = 152). A Cox multivariable model was used to select variables that were predictive of overall survival (OS). RESULTS: In multivariable analysis, the following risk factors were identified as being associated with OS: age greater than 60 years, anemia (hemoglobin < 10 g/dL), thrombocytopenia (platelets < 100 × 109/L), presence of one high molecular risk gene mutation (ie, in SRSF2, ASXL1, and/or RUNX1), and presence of two or more high molecular risk gene mutations. By assigning hazard ratio-weighted points to these variables, the following three risk categories were defined: low risk (median OS, not reached), intermediate risk (median OS, 3.9 years; 95% CI, 2.1 to 5.7 years), and high risk (median OS, 1.9 years; 95% CI, 1.3 to 2.6 years; P < .001). The mutation-adjusted risk score (MARS) was independent of the WHO classification and was confirmed in the independent validation set. During a median follow-up time of 2.2 years (range, 0 to 23 years), 63 (16%) of 383 patients experienced a leukemic transformation to secondary mast cell leukemia (32%) or secondary acute myeloid leukemia (68%). The MARS was also predictive for leukemia-free survival (P < .001). CONCLUSION: The MARS is a validated, five-parameter, WHO-independent prognostic score that defines three risk groups among patients with AdvSM and may improve up-front treatment stratification for these rare hematologic neoplasms.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jawhar M, Schwaab J, Álvarez-Twose I, et al. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. J Clin Oncol. 2019. PMID: 31509472. doi:10.1200/JCO.19.00640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。